Theralase Technologies Inc. V.TLT

TAR-200

[Camphikefish]

There's a news release from JnJ on May 4th stating their TAR-200 drug shows an 80% CR in BCG nonresponsive patients. I've not followed things closely here for a while. Has anyone else taken a look at this? I'm curious about what everyone thinks about their drug and the study.

[DeathXray33]

"TAR-200 was inserted for 4 consecutive 21-day cycles over 84 days."------------------------------------------------------------- That's insane! It's just going to grow back.

[Alamir1111]

Methods Eligible pts aged ≥18 y had histologically confirmed carcinoma in situ (CIS) ± papillary disease (high-grade Ta, any T1), ECOG performance status 0-2, and persistent or recurrent HR NMIBC with last dose of BCG ≤12 mo prior to CIS diagnosis. TAR-200 was dosed Q3W through Wk 24, then Q12W until Wk 96. Response assessments: cystoscopy and centrally assessed urine cytology, CT/MRI

[Eoganacht]

It's an unusual treatment. They insert a silicone tube into the bladder which slowly releases the drug gemcitabine over a period of a few days to a week. After 21 days they remove the device and immediately put in a new one. They do this 8 times - once every 3 weeks in the first 24 weeks. Then .6 more times - once every 12 weeks up to 96 weeks. So it's a non-stop treatment by way of slow